AT845 (FORCE)
Late-Onset Pompe Disease
Key Facts
About Astellas
Astellas Pharma is a major global pharmaceutical company with a mission to deliver innovative, patient-centric healthcare solutions. Formed in 2005 from the merger of Yamanouchi and Fujisawa, it has established a robust pipeline and commercial portfolio across oncology, urology, immunology, and other therapeutic areas. The company's strategy is built on a multi-modal R&D engine focused on cutting-edge biology, complemented by aggressive external innovation and a strategic push into digital health through its Rx+ and HealthX initiatives to drive sustainable growth.
View full company profileTherapeutic Areas
Other Late-Onset Pompe Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Neuromuscular Program | Creyon Bio | Preclinical |
| AT845 | Astellas Pharma | Phase 1/2 |